

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 205/08, 305/14</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/18164 (43) International Publication Date: 18 August 1994 (18.08.94)</p>
<p>(21) International Application Number: PCT/US94/00669 (22) International Filing Date: 28 January 1994 (28.01.94) (30) Priority Data: 08/011,922 1 February 1993 (01.02.93) US (71) Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK [US/US]; State University of New York, Stony Brook, NY 11794-0001 (US). (72) Inventor: OJIMA, Iwao; 6 Ivy League Lane, Stony Brook, NY 11790 (US). (74) Agent: CALVETTI, Frederick, F.; Morgan & Finnegan, 555 13th Street, N.W., Suite 480 West, Washington, DC 20004 (US).</p>		<p>(81) Designated States: AU, CA, CZ, FI, JP, KR, NO, NZ, PL, RU, SK, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>
<p>(54) Title: PROCESS FOR PREPARATION OF TAXANE DERIVATIVES AND β-LACTAM INTERMEDIATES THEREFOR</p>		
<p>(57) Abstract</p> <p>Taxol (I) is a complex diterpene which is currently considered the most exciting lead in cancer chemotherapy. Taxol possesses high cytotoxicity and strong antitumor activity against different cancers which have not been effectively treated by existing antitumor drugs. However, taxol has a problem with solubility in aqueous media, which may impose some serious limitation in its use. TAXOTERE (III) seems to have antitumor activity superior to taxol with better bioavailability. Taxotère has a modified taxol structure with a modified C-13 side chain. This fact strongly indicates that modification on the C-13 side chain would provide a new series of taxol and TAXOTERE analogues which may have higher potency, better bioavailability and less unwanted toxicity. The present invention provides efficient and practical methods for the syntheses of TAXOTERE and its analogues through β-lactam intermediates and their coupling with baccatin III.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -


PROCESS FOR PREPARATION OF TAXANE
DERIVATIVES AND β -LACTAM INTERMEDIATES THEREFOR

FIELD OF THE INVENTION

The present invention relates to a process for
5 the preparation of taxoid(s) including TAXOTÈRE and its
analogs and the β -lactam intermediates useful in this
process.

BACKGROUND OF THE INVENTION

Taxol (I) is a complex diterpene which is
10 currently considered the most exciting lead in cancer
chemotherapy. Taxol possesses high cytotoxicity and
strong antitumor activity against different cancers which
have not been effectively treated by existing antitumor
drugs. For example, taxol is currently in phase III
15 clinical trials for advanced ovarian cancer, phase II for
breast cancer, and phase I for lung cancers, colon cancer
and acute leukemia.



Although taxol is an extremely important "lead"
in cancer chemotherapy, taxol has a problem with
20 solubility in aqueous media, which may impose some serious
limitation in its use. It is common for improved drugs to
be derived from naturally occurring lead compounds. In
fact, French researchers, Potier, Guéritte-Voegelein,


- 2 -

Guénard et al. have discovered that a modification of the C-13 side chain of taxol brought about a new anticancer agent which seems to have antitumor activity superior to taxol with better bioavailability. This synthetic compound was named "TAXOTÈRE (II)", which has t-butoxycarbonyl instead of benzoyl on the amino group of (2R,3S)-phenylisoserine moiety at the C-13 position and a hydroxyl group instead of an acetoxy group at C-10.

[Colin, M. et al. Eur. Pat. Appl. EP253,738 (1988)].

Taxotère is currently in phase II clinical trial in both United States and Europe. TAXOTÈRE has been synthesized by a semisynthetic process, including a coupling of N-tert-butoxycarbonyl-(2R,3S)-3-phenylisoserine with 10-deacetylbaccatin III with proper protecting groups.

(Denis, J.-N. recently reported (Commercon, A. et al., Tetrahedron Letters, 1992, 33 5185)).




(II)

It is known that the C-13 side chain of taxol, i.e., N-benzoyl-(2R, 3S)-3-phenylisoserine (III) moiety, is crucial for the strong antitumor activity of taxol. (Senilh et al., C.R. Séances Acad. Sci. Ser. 2 1984, 299, 1039; Guéritte-Voegelein et al., Tetrahedron, 1986, 42, 4451, and Mangatal et al., Tetrahedron, 1989, 45, 4177; Guéritte-Voegelein et al. J. Med. Chem. 1991, 34, 992; and Swindell et al., J. Med. Chem. 1992, 35, 145; Mathew, A.E. et al., J. Med. Chem. 1992, 35, 145). Moreover, some modification of the C-13 side chain can provide a new series of taxol analogs which may have higher potency, better bioavailability and less unwanted toxicity, as

- 3 -


exemplified by the discovery of TAXOTÈRE (II).



(III)

Accordingly, the development of an efficient method which can be applied to various analogs of taxol and TAXOTÈRE and analogs thereof, i.e., a method having flexibility and wide applicability, is extremely important and of current demand. It has been shown that such a new and efficient method with flexibility can be developed by using enantiomerically pure β -lactams as key-intermediates [Ojima, I. et al., *J. Org. Chem.*, 1991, 56, 1681; Ojima et al., *Tetrahedron*, 1992, 48, 6985; Holton, R.A., Eur. Patent Appl. EP 400,971 (1990)].

Lithium chiral ester enolate-imine cyclocondensation strategy has been applied to the asymmetric synthesis of the side chain of taxol via a (3*R*,4*S*)-3-hydroxy-4-phenylazotidin-2-one (IV) as the key-intermediate. (Ojima, I. et al., *J. Org. Chem.*, 1991, 56, 1681; Ojima et al., *Tetrahedron*, 1992, 48, 6985)



(IV)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.